文献速递心外重症与机械循环支持

132例左心室辅助装置接受者N端脑钠肽前体水平与运动能力的长期演变

Long-term evolution of N-terminal pro-brain natriuretic peptide levels and exercise capacity in 132 left ventricular assist device recipients.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

该研究回顾性分析了132例单中心左心室辅助装置(LVAD)接受者的记录,旨在描述NT-proBNP水平的长期演变及其与运动能力的相关性。结果显示LVAD植入后NT-proBNP显著下降并趋于稳定,亚极量和极量运动能力均改善,且NT-proBNP与6分钟步行试验及心肺运动试验结果呈显著负相关。

要点

  • LVAD植入后NT-proBNP从9736 ± 1072 ng/l显著下降,14天为4360 ± 545 ng/l(P < 0.0001)。
  • 6分钟步行试验预测距离百分比从0-3个月的50 ± 2%改善至3-6个月的61 ± 2%(P < 0.001)。
  • NT-proBNP与6分钟步行试验(相关系数-0.31,P < 0.0001)及心肺运动试验(相关系数-0.28,P < 0.0001)呈显著负相关。

核心结论

  • LVAD支持后NT-proBNP水平下降,亚极量(6分钟步行试验)和极量运动能力(心肺运动试验)改善,且两者与NT-proBNP呈负相关。

研究设计与样本

  • 回顾性分析132例单中心LVAD接受者记录(HeartMate II/III;HeartWare;2007年3月至2018年1月;平均随访559天)。
  • 以标准化方式采集血样、进行6分钟步行试验和极量心肺运动试验。

主要发现

  • LVAD植入前NT-proBNP为9736 ± 1072 ng/l,植入后14天降至4360 ± 545 ng/l(P < 0.0001),6个月降至1485 ± 139 ng/l(P < 0.0001),之后达到稳态(1年后1592 ± 214 ng/l,5年后1679 ± 311 ng/l)。
  • 6分钟步行试验预测距离百分比:0-3个月为50 ± 2%,3-6个月为61 ± 2%(P < 0.001),6-12个月为66 ± 2%(P = 0.08),之后为64 ± 3%(P = 0.70)。
  • 预期峰值氧耗量百分比:0-3个月为44 ± 2%,3-6个月为49 ± 2%,6-12个月为52 ± 2%,12个月后为53 ± 1%;0-3个月与LVAD支持第一年后相比有显著改善。
  • NT-proBNP与6分钟步行试验结果呈显著中度负相关(相关系数-0.31,P < 0.0001),与心肺运动试验结果呈显著中度负相关(相关系数-0.28,P < 0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a widely used biomarker in clinical practice in the context of heart failure. Little is known about the long-term evolution of NT-proBNP levels in left ventricular assist device (LVAD) recipients. Besides this, the potential correlation of NT-proBNP with exercise capacity on the long term after LVAD implantation has not been previously studied. METHODS: We retrospectively analysed 132 single-centre LVAD recipient records (HeartMate II/III; HeartWare; between March 2007 and January 2018; mean follow-up 559 days). Blood samples, 6-min walking test (6MWT) and maximal cardiopulmonary exercise test were performed in a standardized way. RESULTS: Pre-LVAD NT-proBNP levels were increased (9736 ± 1072 ng/l) and dropped significantly after implantation [14 days: 4360 ± 545 ng/l (P < 0.0001), 6 months: 1485 ± 139 ng/l (P < 0.0001)]. Afterwards a steady state was reached during follow-up (after 1 year: 1592 ± 214 ng/l, after 5 years: 1679 ± 311 ng/l). Submaximal exercise capacity significantly improved postoperatively [percentage of the predicted distance walked during the 6MWT 50 ± 2% (0-3 months); 61 ± 2% (3-6 months, P < 0.001)], with a steady state afterwards [66 ± 2% (6-12 months, P = 0.08); 64 ± 3%, P = 0.70 later on]. We found a gradual increment of percentage of the expected peak oxygen consumption postoperatively [44 ± 2% (0-3 months); 49 ± 2% (3-6 months); 52 ± 2% (6-12 months); 53 ± 1% (after 12 months)] with a significant improvement between 0 and 3 months versus after the first year on LVAD. Furthermore, we showed a significant moderate correlation between NT-proBNP levels and results at both the 6MWT (correlation coefficient: -0.31, P < 0.0001) and cardiopulmonary exercise testing (correlation coefficient: -0.28, P < 0.0001). CONCLUSIONS: NT-proBNP decreased on LVAD support. We showed that submaximal (6MWT) and maximal exercise capacity (cardiopulmonary exercise testing) improve after LVAD implantation and demonstrated an inverse correlation of both tests with NT-proBNP levels.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Van Edom C, Jacobs S, Fresiello L, et al. Long-term evolution of N-terminal pro-brain natriuretic peptide levels and exercise capacity in 132 left ventricular assist device recipients. Eur J Cardiothorac Surg. 2022. PMID: 35143640. doi:10.1093/ejcts/ezac053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。